News

Queen Silvia of Sweden awarded for becoming Global Ambassador

3 April 2019 – ADI's Chief Executive Paola Barbarino presented Her Majesty Queen Silvia of Sweden with an award for becoming ADI’s Global Ambassador at the Jubilee event for the Queen Silvia Nursing Award at the Royal Palace of Stockholm. [read more]

Biogen and Eisai remain committed after discontinuation of ENGAGE and EMERGE programmes

22 March 2019 – Pharmaceutical companies Biogen and Eisai have announced the discontinuation of two Phase 3 trials of aducanumab. The decision came after analysis by an independent monitoring committee indicated the trials were unlikely to succeed. Biogen and Eisai will continue to investigate other treatments for Alzheimer’s disease, including anti-amyloid treatment BAN2401. [read more]

Global Perspective Newsletter for February 2019

The February 2019 edition of our Global Perspective Newsletter is now available. Read the latest news from ADI, our partners and member associations, including updates from the WHO Executive Board; the Korean National Institute (KNID)'s symposium; Dementia Alliance International, and much more. [read it now]

El Informe Mundial sobre el Alzheimer 2018 ya está disponible en español

31 de enero de 2019 – El Informe Mundial sobre el Alzheimer 2018 ya está disponible en español en nuestro sitio web. El informe aborda cuestiones claves en la investigación de la demencia, sobre ciencia básica, diagnóstico, descubrimiento de fármacos, reducción de riesgos, epidemiología y cuidados. Descubre lo que tienen que decir los principales investigadores de la demencia a nivel mundial. [Lea más] [read more]

Roche remain committed after discontinuing CREAD programme

30 January 2019 – Pharmaceutical company Roche has announced the discontinuation of their CREAD programme. This was following the finding of two Phase III trials that crenezumab, a possible new drug treatment for Alzheimer’s disease, was not expected to meet its efficacy targets. The Alzheimer’s Prevention Initiative (API) will continue to investigate crenezumab in a pivotal trial to prevent Alzheimer’s disease in healthy people with familial Alzheimer’s disease. Crenezumab was discovered by Swiss biotechnology company AC Immune SA and developed by Roche. [read more]

Looking back, looking forward

14 December 2018 – What a great year 2018 has been for ADI! Amongst many highlights we have gained six new members, hosted four Alzheimer University training programmes, released four major reports, and seen the development of three new national dementia plans. [read more]

Global Perspective Newsletter for December 2018

The December 2018 edition of our Global Perspective Newsletter is now available. Read the latest news from ADI, our partners and member associations, including updates from the mhGAP Forum; World Innovation Summit for Health (WISH) Qatar 2018; the 28th Alzheimer Europe Conference; Dementia Alliance International, and much more. [read it now]

Queen Silvia of Sweden becomes ADI Ambassador

06 December 2018 – Her Majesty Queen Silvia of Sweden has become an Honorary  Ambassador of Alzheimer’s Disease International (ADI), in recognition of her  personal commitment to work surrounding elderly and end of life care, and specifically dementia. [read more]

COGNISANCE Project awarded funding from JPND

06 December 2018 – ADI will be an external collaborator in COGNISANCE, as will our partner Dementia Alliance International (DAI). The COGNISANCE Project (Co-designing dementia diagnosis and post-diagnostic care) is one of 10 to receive funding from the EU Joint Programme on Neurodegenerative Disease Research (JPND). [read more]

ADI announces “Let’s Talk About Dementia Research” webinar series

23 October 2018 - On November 21, 2018 ADI will hold the first in a series of three webinars; creating a unique opportunity for the general public and Alzheimer and dementia associations to engage directly with health and social care professionals and companies involved in dementia research and clinical trials. [read more]